[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Dalloul M, Sherer DM, Gorelick C, Serur E, Zinn H, Sanmugarajah J, Zigalo A, Abulafia O: Transient bilateral ovarian enlargement associated with large retroperitoneal lymphoma. Ultrasound Obstet Gynecol; 2007 Feb;29(2):236-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign causes of ovarian enlargement include luteomas, tumors such as mature cystic teratomas, fibrothecomas, cystadenomas and rare conditions including capillary hemangioma and massive edema of the ovaries.
  • Primary malignancies that may exhibit metastases to the ovaries include gastrointestinal, breast and soft tissue tumors such as lymphoma.
  • We present an unusual case in which a patient presenting with weakness and mild lower abdominal and pelvic pain was noted at sonography to have bilaterally enlarged ovaries with features similar to those of massive ovarian edema as described previously, which has been associated with venous and lymphatic obstruction.
  • Subsequent computerized tomography (CT) imaging depicted a large retroperitoneal tumor, CT-guided biopsy of which revealed diffuse large B cell lymphoma.
  • The patient responded well to chemotherapy with significant shrinkage of the tumor, and reappearance of normal findings on ovarian sonography.
  • [MeSH-minor] Adult. Female. Humans. Hypertrophy / etiology. Hypertrophy / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 17252529.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Bergan J, Pascarella L, Mekenas L: Venous disorders: treatment with sclerosant foam. J Cardiovasc Surg (Torino); 2006 Feb;47(1):9-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous disorders: treatment with sclerosant foam.
  • AIM: Treatment of venous insufficiency has been revolutionized by introduction of less invasive endovenous procedures.
  • The idea of using air and drug in combination is quite old.
  • This report documents experience in treating severe chronic venous insufficiency (CVI), venous angiomata and varicose veins using foam sclerotherapy.
  • METHODS: This report describes initial experience in treating 332 patients: 261 patients with varicose veins, 56 patients (77 limbs) with severe CVI, 6 patients with venous angiomata and 9 patients with Klippel-Trenaunay (KT) syndrome.
  • A compounding pharmacy supplied the 1-3% polidocanol that was prescribed for each patient according to guidelines on the Food and Drug Administration (FDA) website.
  • Venous access was obtained percutaneously through varices for saphenous vein and variceal closure and through specific targeted veins for treatment of CVI, angiomata and KT syndrome.
  • Deep venous thrombosis (DVT) surveillance was done at 1, 7, 30, and 60 days.
  • Foam volumes varied from 1 to 16 mL for each treatment.
  • RESULTS: Obliteration of varicose and saphenous veins was entirely satisfactory (2.89 treatments/limb).
  • There was no disability down time, no need for analgesics or sedation.
  • Treatment goals but not cure were achieved in limbs with angiomata and KT syndrome.
  • Treatment of CVI resulted in rapid, 2-6 weeks, ulcer healing, relief of painful lipodermatosclerosis and dermatitis and some decrease in skin hyperpigmentation.
  • There was one failure in 77 limbs treated for CVI and one case of cutaneous necrosis in one limb treated for CVI and another in a limb treated for angiomata.
  • CONCLUSIONS: Treatment of a variety of venous disorders can be accomplished using foam sclerotherapy with results comparable to surgery and with an acceptably low rate of adverse events.
  • [MeSH-major] Sclerosing Solutions / administration & dosage. Sclerotherapy. Varicose Veins / therapy. Venous Insufficiency / therapy

  • MedlinePlus Health Information. consumer health - Varicose Veins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434941.001).
  • [ISSN] 0021-9509
  • [Journal-full-title] The Journal of cardiovascular surgery
  • [ISO-abbreviation] J Cardiovasc Surg (Torino)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Sclerosing Solutions
  •  go-up   go-down


3. Moriguchi A, Iwahashi K, Onishi Y, Kita H, Nishio A, Kanno T, Matsuura T, Ikezawa K, Ono A, Mizuno T, Chiba M, Maeda K, Aketa H, Naito M, Michida T, Katayama K, Yamasaki Y, Kasugai T: [An operated case of retroperitoneal venous hemangioma complicated with Kasabach-Merritt syndrome which was well controlled by danaparoid sodium]. Nihon Shokakibyo Gakkai Zasshi; 2009 Nov;106(11):1660-8
MedlinePlus Health Information. consumer health - Blood Thinners.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An operated case of retroperitoneal venous hemangioma complicated with Kasabach-Merritt syndrome which was well controlled by danaparoid sodium].
  • CT and MRI revealed a retroperitoneal tumor, and we diagnosed giant retroperitoneal hemangioma complicated with Kasabach-Merritt syndrome, following blood pool scintigraphy.
  • [MeSH-major] Anticoagulants / therapeutic use. Chondroitin Sulfates / therapeutic use. Dermatan Sulfate / therapeutic use. Disseminated Intravascular Coagulation / drug therapy. Hemangioma / complications. Heparitin Sulfate / therapeutic use. Retroperitoneal Neoplasms / complications

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893297.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anticoagulants; 24967-94-0 / Dermatan Sulfate; 83513-48-8 / danaproid; 9007-28-7 / Chondroitin Sulfates; 9050-30-0 / Heparitin Sulfate
  •  go-up   go-down


Advertisement
4. Pascarella L, Bergan JJ, Yamada C, Mekenas L: Venous angiomata: treatment with sclerosant foam. Ann Vasc Surg; 2005 Jul;19(4):457-64
Hazardous Substances Data Bank. DODECYL ALCOHOL, ETHOXYLATED .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous angiomata: treatment with sclerosant foam.
  • Venous angiomata, or venous malformations, are often present at birth, although they may not be evident until later.
  • Treatment of venous angiomata is often requested for cosmetic reasons, but painful ulcerations, nerve compression, functional disability can command care.
  • During a 30-month period ending March 2004, 1,321 patients were investigated for venous disorders at the Vein Institute of La Jolla.
  • Fourteen (incidence 1%) were found to have venous angiomata (: nine women).
  • Lesions were classified by the Hamburg system and were primarily venous, extratruncular in 12 patients and combined extratruncular and truncular in two patients.
  • Eight patients, three males, had manifestations of lower extremity Klippel-Trenaunay (syndrome; six had only venous angiomas.
  • Magnetic resonance venography was also used to image the lesions, define the deep circulation, note connections with normal circulation, identify vessels for therapeutic access, and determine infiltration of the lesion into adjacent soft tissue.
  • The SonoSite 190 plus Duplex Doppler was used for ultrasound guidance, whenever deep access was required and to monitor progress and effects of treatment.
  • A goal was set for each patient before treatment was begun.
  • Ten patients were treated, and four await treatment.
  • The mean number of treatments was 3.6 +/- 2.8 (range 1-10).
  • Sclerosant foam is a satisfactory tool to use in treating venous angiomata including the Klippel-Trenaunay syndrome.
  • [MeSH-major] Angiomatosis / drug therapy. Arteriovenous Malformations / drug therapy. Polyethylene Glycols / therapeutic use. Sclerosing Solutions / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnostic Imaging. Female. Humans. Klippel-Trenaunay-Weber Syndrome / drug therapy. Magnetic Resonance Imaging. Male. Middle Aged. Ultrasonography, Doppler, Duplex

  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15981122.001).
  • [ISSN] 0890-5096
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sclerosing Solutions; 0AWH8BFG9A / polidocanol; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


5. Condat B, Pessione F, Helene Denninger M, Hillaire S, Valla D: Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology; 2000 Sep;32(3):466-70
MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy.
  • Characteristics and outcomes of recent portal or mesenteric venous thrombosis are ill-known.
  • We intended to compare these features with those of patients with portal cavernoma, and also to assess the incidence of recanalization of recent thrombosis on anticoagulation therapy.
  • All patients seen between 1983 and 1999 were enrolled into this retrospective study if recent portal or mesenteric venous thrombosis or portal cavernoma had been documented, and if cancer of the liver, pancreas, or bile duct, intrahepatic block including cirrhosis, and obstruction of the hepatic veins had been ruled out.
  • In conclusion, mesenteric or portal venous thrombosis is increasingly recognized at an early stage.
  • The features differentiating recent thrombosis and cavernoma are related to silent onset precluding early recognition and therapy in the latter.
  • Frequent association with prothrombotic states and frequent recanalization on anticoagulation support the recommendation of early anticoagulation therapy in all patients with recent portal vein thrombosis.
  • [MeSH-major] Anticoagulants / therapeutic use. Mesenteric Veins. Portal Vein. Venous Thrombosis / drug therapy
  • [MeSH-minor] Adult. Female. Hemangioma, Cavernous / drug therapy. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Portal thrombosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10960436.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


6. Fulkerson DH, Agim NG, Al-Shamy G, Metry DW, Izaddoost SA, Jea A: Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: case report and literature review. Childs Nerv Syst; 2010 Dec;26(12):1799-805
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: case report and literature review.
  • PURPOSE: We report an extremely rare case of a patient with a large, cervical, and upper thoracic cutaneous hemangioma associated with a separate, underlying mediastinal hemangioma extending to the epidural space causing significant spinal cord compression.
  • She underwent emergent surgical decompression and medical therapy with propranolol and systemic corticosteroids.
  • CONCLUSION: While several recent reports have described dramatic responses of hemangiomas to propranolol, this is the first case in which it was used as part of a multimodal approach to symptomatic spinal cord compression.
  • She is neurologically intact and has radiographic regression of the hemangiomas on follow-up examination 6 months later.
  • [MeSH-major] Decompression, Surgical / adverse effects. Hemangioma, Capillary / drug therapy. Hemangioma, Capillary / surgery. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / surgery. Spinal Cord Compression / surgery
  • [MeSH-minor] Adrenergic beta-Antagonists / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Anticoagulants / therapeutic use. Child, Preschool. Female. Heparin / therapeutic use. Humans. Postoperative Complications / drug therapy. Postoperative Complications / etiology. Prednisolone / therapeutic use. Propranolol / therapeutic use. Venous Thrombosis / drug therapy. Venous Thrombosis / etiology

  • Genetic Alliance. consumer health - Hemangioma.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet A. 2006 May 1;140(9):975-86 [16575892.001]
  • [Cites] Pediatrics. 2009 Nov;124(5):1447-56 [19858157.001]
  • [Cites] Arch Dermatol. 2001 Sep;137(9):1208-13 [11559219.001]
  • [Cites] N Engl J Med. 1992 May 28;326(22):1456-63 [1489383.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):416-21 [7705821.001]
  • [Cites] Pediatr Dermatol. 2009 Sep-Oct;26(5):610-4 [19840322.001]
  • [Cites] N Engl J Med. 2008 Jun 12;358(24):2649-51 [18550886.001]
  • [Cites] J Pediatr. 1968 Mar;72(3):351-7 [5639749.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):882-7 [16950977.001]
  • [Cites] J Pediatr Surg. 1992 Oct;27(10):1291-3 [1403505.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2002 May;38(5):298-304 [12418927.001]
  • [Cites] Pediatrics. 2009 Sep;124(3):e423-31 [19706583.001]
  • [Cites] Pediatr Dermatol. 2005 Sep-Oct;22(5):383-406 [16190987.001]
  • [Cites] Arch Dermatol. 1977 Nov;113(11):1587-90 [931402.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2009 Dec;73(12):1821-3 [19796830.001]
  • [Cites] Arch Dermatol. 2010 Dec;146(12):1391-6 [20713775.001]
  • [Cites] Arch Dermatol. 2002 Dec;138(12):1567-76 [12472344.001]
  • [Cites] N Engl J Med. 2008 Dec 25;359(26):2846; author reply 2846-7 [19109584.001]
  • [Cites] Neuroradiology. 1978;16:82-4 [740218.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1465-6 [19453811.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):11-22 [10665907.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):643-6 [9386676.001]
  • [Cites] Pediatrics. 1989 Jun;83(6):977-80 [2657627.001]
  • [Cites] Neuropediatrics. 1990 Aug;21(3):160-1 [2234322.001]
  • [Cites] Pediatr Dermatol. 2008 Mar-Apr;25(2):168-73 [18429772.001]
  • [Cites] J Neurosurg Pediatr. 2009 May;3(5):429-34 [19409024.001]
  • [Cites] Arch Dermatol. 2004 May;140(5):591-6 [15148105.001]
  • [Cites] Pediatr Neurol. 2008 Dec;39(6):423-5 [19027589.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2009 Aug;73(8):1168-72 [19481268.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 May;30(5):1005-13 [19213817.001]
  • [Cites] Ann Surg. 1915 Dec;62(6):641-9 [17863459.001]
  • [Cites] Pediatr Radiol. 1999 Jul;29(7):517-9 [10398787.001]
  • [Cites] J Neurosurg Spine. 2005 Sep;3(3):249-52 [16235712.001]
  • [Cites] J Am Acad Dermatol. 2003 Apr;48(4):477-93; quiz 494-6 [12664009.001]
  • [Cites] J Dtsch Dermatol Ges. 2010 Mar;8(3):184-6 [19788583.001]
  • [Cites] Pediatr Dermatol. 2008 Mar-Apr;25(2):193-5 [18429777.001]
  • [Cites] Laryngoscope. 2009 Oct;119(10):2051-4 [19650125.001]
  • [Cites] Plast Reconstr Surg. 1967 Jan;39(1):76-83 [6018814.001]
  • [Cites] Eur J Pediatr Surg. 2002 Dec;12(6):366-74 [12548487.001]
  • (PMID = 20405131.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 0 / Anti-Inflammatory Agents; 0 / Anticoagulants; 9005-49-6 / Heparin; 9PHQ9Y1OLM / Prednisolone; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


7. Maruyama I, Ohguro H, Nakazawa M: A case of acute angle-closure glaucoma secondary to posterior scleritis in patient with Sturge-Weber syndrome. Jpn J Ophthalmol; 2002 Jan-Feb;46(1):74-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sturge-Weber syndrome has been known to be frequently associated with facial cutaneous angioma and ipsilateral glaucoma.
  • OBSERVATIONS: Slit-lamp examination revealed diffuse episcleral venous hemangioma in the right eye.
  • The patient responded well to treatment with systemic corticosteroids and cycloplegics.
  • [MeSH-minor] Acute Disease. Adolescent. Anterior Eye Segment / pathology. Anterior Eye Segment / radiography. Anterior Eye Segment / ultrasonography. Antihypertensive Agents / therapeutic use. Betamethasone / therapeutic use. Drug Therapy, Combination. Glucocorticoids / therapeutic use. Humans. Intraocular Pressure. Male. Mydriatics / therapeutic use. Tomography, X-Ray Computed


8. Shroff PK, Martin TW, Schmitz ML: Successful anesthetic management of a child with an extensive facial hemangioma and high output cardiac failure for placement of a central venous catheter. Paediatr Anaesth; 2006 Jan;16(1):77-81
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful anesthetic management of a child with an extensive facial hemangioma and high output cardiac failure for placement of a central venous catheter.
  • A two-and-a-half-year-old female with an extensive facial and lingual hemangioma, associated high output cardiac failure, and a history of difficult intubation presented for central venous catheter (CVC) placement for vincristine chemotherapy.
  • [MeSH-major] Anesthetics, Inhalation. Cardiac Output, High / complications. Catheterization, Central Venous. Facial Neoplasms / surgery. Hemangioma / surgery. Laryngeal Masks. Methyl Ethers
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / adverse effects. Antineoplastic Agents, Phytogenic / therapeutic use. Child, Preschool. Female. Humans. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • Hazardous Substances Data Bank. Sevoflurane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409535.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anesthetics, Inhalation; 0 / Antineoplastic Agents, Phytogenic; 0 / Methyl Ethers; 38LVP0K73A / sevoflurane; 5J49Q6B70F / Vincristine
  •  go-up   go-down


9. Yang Y, Sun M, Hou R, Yan Z, Wang L, Cheng X, Lei D, Liu Y: Preliminary study of fibrin glue combined with pingyangmycin for the treatment of venous malformations in the oral and maxillofacial region. J Oral Maxillofac Surg; 2008 Nov;66(11):2219-25
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary study of fibrin glue combined with pingyangmycin for the treatment of venous malformations in the oral and maxillofacial region.
  • PURPOSE: To observe the outcome of using fibrin glue (FG) combined with Pingyangmycin (Tianjin Taihe Pharmaceutical Co Ltd, Tianjin, China) in the treatment of venous malformations (VMs) in the oral and maxillofacial region.
  • MATERIALS AND METHODS: The treatment data of 7 patients with VMs from January 2005 to January 2006 were reviewed.
  • The therapeutic effect was evaluated by clinical examination and Doppler ultrasonography.
  • The follow-up time was from 1 to 2 years.
  • Two patients had a fever during treatment, and one of them stopped treatment because of continuous high fever.
  • No allergic reactions, pulmonary embolisms, or other complications were found during or after treatment.
  • CONCLUSION: The therapeutic modality of FG combined with Pingyangmycin for VMs in the oral and maxillofacial region was effective, and the extent of morbidity was acceptable.
  • However, the further long-term observation of severe complications such as deep venous thrombosis and pulmonary embolism should be performed in additional biological and clinical studies.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Arteriovenous Malformations / therapy. Bleomycin / analogs & derivatives. Facial Neoplasms / therapy. Fibrin Tissue Adhesive / administration & dosage. Hemangioma, Cavernous / therapy. Mouth Neoplasms / therapy. Sclerosing Solutions / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Drug Combinations. Female. Humans. Injections, Intralesional. Magnetic Resonance Angiography. Male. Treatment Outcome. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940483.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Drug Combinations; 0 / Fibrin Tissue Adhesive; 0 / Sclerosing Solutions; 11056-06-7 / Bleomycin; 11116-32-8 / bleomycetin
  •  go-up   go-down


10. Russell S, Watts RG, Royal SA, Barnhart DC: Group A streptococcal infection of an intramuscular venous malformation: a case report and review of the literature. Pediatr Emerg Care; 2008 Dec;24(12):839-41
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Group A streptococcal infection of an intramuscular venous malformation: a case report and review of the literature.
  • Intramuscular venous malformations are uncommon benign masses of vascular origin that can occur anywhere in the body.
  • They can be small and clinically insignificant or can be large and violate tissue planes and viscera.
  • Rarely, venous malformations can get infected and present with fever or other more severe systemic symptoms.
  • The literature is sparse regarding infection of intramuscular venous malformations.
  • [MeSH-major] Hemangioma, Cavernous / diagnosis. Muscle Neoplasms / diagnosis. Muscle, Skeletal / blood supply. Myositis / etiology. Streptococcal Infections / etiology. Streptococcus pyogenes / isolation & purification
  • [MeSH-minor] Biopsy. Calcinosis / etiology. Calcinosis / radiography. Child, Preschool. Clindamycin / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Drug Therapy, Combination. Fever / etiology. Hemangiosarcoma / diagnosis. Humans. Male. Rhabdomyosarcoma / diagnosis. Tomography, X-Ray Computed. Vancomycin / therapeutic use

  • Genetic Alliance. consumer health - Venous Malformation.
  • MedlinePlus Health Information. consumer health - Myositis.
  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092562.001).
  • [ISSN] 1535-1815
  • [Journal-full-title] Pediatric emergency care
  • [ISO-abbreviation] Pediatr Emerg Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 3U02EL437C / Clindamycin; 6Q205EH1VU / Vancomycin
  • [Number-of-references] 16
  •  go-up   go-down


11. Baud AV, Breton P, Guibaud L, Freidel M: [Treatment of low-pressure vascular malformations by injection of Ethibloc. Study of 19 cases and analysis of complications]. Rev Stomatol Chir Maxillofac; 2000 Oct;101(4):181-8
Hazardous Substances Data Bank. DIATRIZOATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of low-pressure vascular malformations by injection of Ethibloc. Study of 19 cases and analysis of complications].
  • [Transliterated title] Traitement des malformations vasculaires à bas débit par injection d'Ethibloc. Etude de 19 cas et analyse des complications.
  • Out of 10 venous angiomas, 5 entirely disappeared, 3 considerably decreased and 2 remained unaltered.
  • Post-treatment complications consisted in a local inflammatory reaction.
  • It materialized as an Ethibloc exteriorization among 5 patients suffering from venous angiomas and 3 patients suffering from lymphangiomas and as an inflammatory lump for 2 venous angiomas carriers and for 4 lymphangiomas carriers.
  • These satisfactory results (volume decreasing in 90% of the malformations) as well as the mildness of the side effects encourage to use Ethibloc in the treatment of low flow vascular malformations.
  • In our experience, Ethibloc is particularly appropriate for the treatment of large lymphangiomas.
  • [MeSH-major] Arteriovenous Malformations / therapy. Diatrizoate / therapeutic use. Fatty Acids / therapeutic use. Lymphangioma, Cystic / therapy. Propylene Glycols / therapeutic use. Sclerosing Solutions / therapeutic use. Sclerotherapy / methods. Zein / therapeutic use
  • [MeSH-minor] Adult. Child. Child, Preschool. Drug Combinations. Female. Granuloma / etiology. Head and Neck Neoplasms / therapy. Hemangioma / therapy. Humans. Infant. Infant, Newborn. Lung Neoplasms / therapy. Male. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Vascular Malformations.
  • MedlinePlus Health Information. consumer health - Arteriovenous Malformations.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11103425.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Fatty Acids; 0 / Propylene Glycols; 0 / Sclerosing Solutions; 117-96-4 / Diatrizoate; 9010-66-6 / Zein; 91196-33-7 / alcoholic prolamine solution
  •  go-up   go-down


12. Halperin EC: Neonatal neoplasms. Int J Radiat Oncol Biol Phys; 2000 Apr 1;47(1):171-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe neoplasms diagnosed in children </= 28 days of age along with their treatment, associated congenital anomalies, and the long-term consequences of the diagnoses and treatments.
  • The 20 patients identified via the computerized registry system for 1980-1998 constitute 2% (20/925) of all neoplasms seen in patients </= 16 years of age over this same time period at DUMC.
  • The histologic diagnoses were teratoma/germ cell tumor (n = 8, 35%), neuroblastoma (n = 5, 22%), retinoblastoma (n = 4, 17%), primary central nervous system (CNS) tumor (n = 3, 13%), and one case each of rhabdomyosarcoma, glossal glial choristoma, and hemangioma in the setting of Kasabach-Merritt Syndrome.
  • The one patient with malignant germ cell tumor, treated with surgery and chemotherapy, died.
  • Two were treated with surgery + chemotherapy + radiotherapy; two with surgery + chemotherapy; and one with surgery alone.
  • Associated congenital anomalies and medical problems were ventricular septal defect, seizure disorder, and Fanconi's anemia.
  • A child with a dumbbell neuroblastoma, treated with surgery and chemotherapy, is paraplegic.
  • The two children with trilateral retinoblastoma died after therapy with surgery, craniospinal and orbital irradiation, and chemotherapy.
  • Two children with bilateral disease are long-term survivors: one treated with radiotherapy + chemotherapy and one with radiotherapy alone.
  • Two of the patients are long-term survivors after surgery + chemotherapy.
  • Six children received eight courses of radiation therapy: 2 for Stage 4S neuroblastoma with respiratory compromise from an enlarging liver and 4 for retinoblastoma.
  • The two infants with trilateral retinoblastoma received two courses of irradiation each: one of the treatment of intraocular tumor and a second, at an older age, for the pineal tumor.
  • The most serious complication of anesthesia was a case of enterobacter cloacae sepsis in the central venous access line used for repetitively administering the anesthetic.
  • Radiation therapy is administered infrequently in a population highly susceptible to late ill effects.
  • When radiotherapy is required, anesthesia may be repetitively administered to aid in reproducible treatment.
  • [MeSH-minor] Anesthesia. Brain Neoplasms / epidemiology. Brain Neoplasms / pathology. Brain Neoplasms / therapy. Female. Follow-Up Studies. Hemangioma / epidemiology. Hemangioma / pathology. Hemangioma / therapy. Humans. Infant, Newborn. Male. Neuroblastoma / epidemiology. Neuroblastoma / pathology. Neuroblastoma / therapy. Registries. Retinoblastoma / epidemiology. Retinoblastoma / pathology. Retinoblastoma / therapy. Survivors. Teratoma / epidemiology. Teratoma / pathology. Teratoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758320.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


13. Cohen SP, Abdi S: Venous malformations associated with central pain: report of a case. Anesth Analg; 2002 Nov;95(5):1358-60, table of contents
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous malformations associated with central pain: report of a case.
  • IMPLICATIONS: The authors describe an unusual case of central pain (CP) that resulted from giant venous hemangiomas.
  • The patient was treated with a variety of medications, including the N-methyl-D-aspartate antagonist dextromethorphan.
  • We report the first known association between venous malformations and CP and briefly describe why the use of dextromethorphan in this disorder requires further evaluation.
  • [MeSH-major] Dextromethorphan / therapeutic use. Excitatory Amino Acid Antagonists / therapeutic use. Intracranial Arteriovenous Malformations / complications. Intracranial Arteriovenous Malformations / pathology. Ketamine / therapeutic use. Pain / drug therapy. Pain / etiology. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • [MeSH-minor] Analgesics, Opioid / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Oxycodone / therapeutic use. Pain Measurement

  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. DEXTROMETHORPHAN .
  • Hazardous Substances Data Bank. KETAMINE .
  • Hazardous Substances Data Bank. OXYCODONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12401626.001).
  • [ISSN] 0003-2999
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Excitatory Amino Acid Antagonists; 0 / Receptors, N-Methyl-D-Aspartate; 690G0D6V8H / Ketamine; 7355X3ROTS / Dextromethorphan; CD35PMG570 / Oxycodone
  •  go-up   go-down


14. Ho V, Krol A, Bhargava R, Osiovich H: Diffuse neonatal haemangiomatosis. J Paediatr Child Health; 2000 Jun;36(3):286-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Hemangioma / diagnosis. Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Central Nervous System Venous Angioma / diagnosis. Central Nervous System Venous Angioma / drug therapy. Drug Therapy, Combination. Fatal Outcome. Female. Humans. Infant, Newborn. Interferon-alpha / administration & dosage. Magnetic Resonance Imaging. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10849236.001).
  • [ISSN] 1034-4810
  • [Journal-full-title] Journal of paediatrics and child health
  • [ISO-abbreviation] J Paediatr Child Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


15. Dòmini M, Aquino A, Fakhro A, Tursini S, Marino N, Di Matteo S, Lelli Chiesa P: Blue rubber bleb nevus syndrome and gastrointestinal haemorrhage: which treatment? Eur J Pediatr Surg; 2002 Apr;12(2):129-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blue rubber bleb nevus syndrome and gastrointestinal haemorrhage: which treatment?
  • PURPOSE: To describe a paediatric case of "Blue Rubber Bleb Nevus Syndrome" (BRBNS) or Bean's syndrome, a rare systemic disorder characterised by cutaneous and gastrointestinal vascular malformations that often lead to overt life-threatening gastrointestinal bleeding or occult blood loss with severe anaemia and iron deficiency.
  • A few months previously she was endoscopically treated for gastric angiomas which developed into melaena.
  • At laparotomy, more than 25 angiomas of the GI tract were found.
  • CONCLUSIONS: BRBNS belongs to the group of vascular venous malformations.
  • Most of the time it occurs sporadically, but it can be inherited as an autosomal dominant trait.
  • Recent analysis identified a locus on chromosome 9 responsible for venous malformations.
  • Treatment is dependent on the extent of gut involvement and the severity of the clinical picture.
  • In the absence of massive bleeding, a conservative treatment will be sufficient; otherwise resections are mandatory, but additional lesions may subsequently develop.
  • Pharmacological treatment is useless.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Gastrointestinal Neoplasms / surgery. Hemangioma / surgery. Nevus, Blue / surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Blue Rubber Bleb Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12015660.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Agnese M, Cipolletta L, Bianco MA, Quitadamo P, Miele E, Staiano A: Blue rubber bleb nevus syndrome. Acta Paediatr; 2010 Apr;99(4):632-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blue Rubber Bleb Nevus Syndrome (BRBNS) is a rare condition characterized by multiple venous malformations involving the skin and internal organs.
  • We describe a 10-year-old girl who, since birth, presented numerous venous malformations all over her body and a lymphangioma in the right leg.
  • The endoscopic examination of the gastrointestinal tract revealed multiple giant venous malformations in the oesophagus, stomach, duodenum and in all visible sections of the colon.
  • Endoscopy is the gold standard technique for the diagnosis of BRBNS with GI lesions and also allows immediate therapeutic measures such as argon plasma coagulation, laser photocoagulation, sclerotherapy or band ligation.
  • In addition, pharmacological treatments based on corticosteroids, interferon alfa, vincristine or octreotide have been described for BRBNS.
  • The treatment is based on pharmacological or surgical therapy.
  • [MeSH-major] Gastrointestinal Neoplasms / pathology. Hemangioma / pathology. Nevus, Blue / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Blue Rubber Bleb Nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958301.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


17. Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO: Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int; 2004 Jan;19(12):766-73
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations.
  • Successful treatment of vascular anomalies has eluded the physician until now, despite various treatments utilised.
  • Bleomycin has been successfully used in intralesional injection treatment of cystic hygromas and haemangiomas, based specifically on a high sclerosing effect on vascular endothelium.
  • In a prospective study of 95 patients, the effectiveness of intralesional bleomycin injection (IBI) treatment in haemangiomas and vascular malformations was evaluated and documented.
  • Complete resolution occurred in 49% of haemangiomas, 32% of venous malformations, and 80% of cystic hygromas.
  • Significant improvement occurred in 38% of haemangiomas, 52% of venous malformations, 13% of cystic hygromas and 50% of lymphatic malformations.
  • Of the six patients who presented with a painful lesion, four experienced complete resolution and two had significant improvement to treatment.
  • IBI is an effective treatment in haemangiomas and vascular malformation lesions, obviating the need for invasive primary surgery or systemic treatment regimens in 80% of cases, and allowing for limited need of secondary surgical or adjunctive procedures in cases with a moderate result.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Cardiovascular Abnormalities / drug therapy. Hemangioma / drug therapy. Lymphangioma, Cystic / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Infant. Infant, Newborn. Injections, Intralesional. Male. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Vascular Malformations.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Apr;31(4):903-14 [4122362.001]
  • [Cites] Plast Reconstr Surg. 1999 Nov;104(6):1616-23 [10541160.001]
  • [Cites] Australas J Dermatol. 2000 Nov;41 Suppl:S89-91 [11105389.001]
  • [Cites] Plast Reconstr Surg. 1999 Jul;104(1):1-11; discussion 12-5 [10597669.001]
  • [Cites] Eur J Nucl Med. 1993 Feb;20(2):114-8 [7679991.001]
  • [Cites] Mayo Clin Proc. 1992 Aug;67(8):739-47 [1434912.001]
  • [Cites] Eur J Pediatr Surg. 1997 Jun;7(3):158-62 [9241503.001]
  • [Cites] Radiology. 2000 Oct;217(1):127-32 [11012433.001]
  • [Cites] Curr Probl Surg. 2000 Aug;37(8):517-84 [10955029.001]
  • [Cites] J Pediatr Surg. 1995 Sep;30(9):1282-7 [8523225.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Jan;125(1):21-7 [9932582.001]
  • [Cites] J Pediatr Surg. 1992 Apr;27(4):440-3 [1381746.001]
  • [Cites] Arch Dermatol. 2000 Jul;136(7):905-14 [10890993.001]
  • [Cites] Pediatrics. 1990 Apr;85(4):491-8 [2097998.001]
  • [Cites] Plast Reconstr Surg. 1989 Mar;83(3):459-67 [2919200.001]
  • [Cites] Cancer Treat Rev. 1983 Dec;10(4):221-43 [6198083.001]
  • [Cites] Am J Ophthalmol. 1989 May 15;107(5):518-22 [2540659.001]
  • [Cites] N Engl J Med. 1999 Jul 15;341(3):173-81 [10403856.001]
  • [Cites] J Antibiot B. 1966 Apr 20;19(1):21-7 [5338400.001]
  • [Cites] Ophthalmic Surg. 1986 Apr;17(4):229-31 [3714192.001]
  • [Cites] Cancer. 1987 Aug 15;60(4):741-9 [2439189.001]
  • [Cites] Plast Reconstr Surg. 1995 Feb;95(2):305-12 [7824610.001]
  • [Cites] Mutat Res. 1990 Sep;232(1):57-61 [1697038.001]
  • [Cites] Int Surg. 1997 Jan-Mar;82(1):49-51 [9189802.001]
  • [Cites] J Dermatol. 1997 Nov;24(11):701-10 [9433027.001]
  • (PMID = 14740248.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  • [Number-of-references] 31
  •  go-up   go-down


18. Vabres P: [What's new in pediatric dermatology?]. Ann Dermatol Venereol; 2008 Dec;135 Suppl 7:S343-53
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main selected articles in pediatric dermatology covered the following topics: development and maturation of the epidermal barrier in the neonate, iatrogenic events in the neonatal ICU, diagnostic value of minor birthmarks, complications, risk factors and treatment of hemangiomas, coagulopathy in venous malformations, epidemiology and dermoscopy of congenital and acquired melanocytic nevi in childhood, growth of the body surface area, new pathogenic concepts and treatment in atopic dermatitis, the impact of filaggrin deficiency, hereditary factors in Kawasaki disease, severe and drug resistant cases, management of juvenile dermatomyositis, treatment of childhood psoriasis with biologics, the new classification of epidermolysis bullosa and therapeutic approach with cell therapy, neurological impairment in xeroderma pigmentosum, behavioural anomalies in X-linked ichthyosis, guidelines for neurofibromatosis type I, the genetics of an hereditary hypotrichosis, infantile acne, rosacea in childhood, mast cell disease management and, last but not least, treatment of hair lice with silicone.
  • [MeSH-major] Dermatologic Agents / therapeutic use. Dermatology / trends. Pediatrics / trends. Skin Diseases / drug therapy. Skin Diseases / genetics
  • [MeSH-minor] Acne Vulgaris / drug therapy. Acne Vulgaris / genetics. Child. Dermatitis, Atopic / drug therapy. Dermatitis, Atopic / genetics. Dermatomyositis / drug therapy. Dermatomyositis / genetics. Epidermolysis Bullosa / drug therapy. Epidermolysis Bullosa / genetics. Hemangioma / drug therapy. Hemangioma / genetics. Humans. Hypotrichosis / drug therapy. Hypotrichosis / genetics. Ichthyosis / drug therapy. Ichthyosis / genetics. Mastocytosis / drug therapy. Mastocytosis / genetics. Mucocutaneous Lymph Node Syndrome / drug therapy. Mucocutaneous Lymph Node Syndrome / genetics. Neurofibromatosis 1 / drug therapy. Neurofibromatosis 1 / genetics. Nevus, Pigmented / drug therapy. Nevus, Pigmented / genetics. Psoriasis / drug therapy. Psoriasis / genetics. Risk Factors. Rosacea / drug therapy. Rosacea / genetics. Xeroderma Pigmentosum / drug therapy. Xeroderma Pigmentosum / genetics

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19264210.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Dermatologic Agents
  • [Number-of-references] 90
  •  go-up   go-down


19. Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C, Bruix J: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology; 2008 Jan;47(1):97-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FNB was repeated up to 3 times and on detection of change in aspect/size.
  • Intense arterial contrast uptake followed by washout in the delayed/venous phase was registered as conclusive for HCC.
  • Final diagnoses were: HCC (n = 60), cholangiocarcinoma (n = 1), and benign lesions (regenerative/dysplastic nodule, hemangioma, focal nodular hyperplasia) (n = 28).

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2008 Jun;47(6):2145-6; author reply 2146-7 [18508292.001]
  • [CommentIn] Hepatology. 2008 Jun;47(6):2145; author reply 2146-7 [18508306.001]
  • [ErratumIn] Hepatology. 2008 Feb;47(2):769
  • (PMID = 18069697.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / 1R01DK076986-0
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


20. Meyer V, Schneider SW, Görge T: [Dermatologic aspects of anticoagulation]. Hautarzt; 2010 Aug;61(8):705-16; quiz 717-8
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Iatrogenic manipulation of this highly regulated system is possible with a variety of therapeutic agents.
  • [MeSH-major] Anticoagulants / therapeutic use. Skin Diseases / drug therapy. Thrombophlebitis / drug therapy
  • [MeSH-minor] Disseminated Intravascular Coagulation / blood. Disseminated Intravascular Coagulation / drug therapy. Erysipelas / blood. Erysipelas / drug therapy. Hemangioma / drug therapy. Hemangioma, Capillary / blood. Hemangioma, Capillary / drug therapy. Hemostasis / drug effects. Hemostasis / physiology. Humans. Kasabach-Merritt Syndrome. Skin Neoplasms / drug therapy. Sneddon Syndrome / blood. Sneddon Syndrome / drug therapy. Stevens-Johnson Syndrome / blood. Stevens-Johnson Syndrome / drug therapy. Venous Thrombosis / blood. Venous Thrombosis / prevention & control

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1944 May;20(3):651-9 [19970770.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 8;104(19):7899-903 [17470810.001]
  • [Cites] Pathophysiol Haemost Thromb. 2008;36(5):271-4 [19996638.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2005 Jan;29(1):74-7 [15570275.001]
  • [Cites] J Vasc Surg. 2002 Jul;36(1):191-3 [12096280.001]
  • [Cites] J Clin Oncol. 2009 Oct 10;27(29):4834-8 [19738116.001]
  • [Cites] J Thromb Haemost. 2007 Mar;5(3):583-9 [17166247.001]
  • [Cites] Circulation. 1959 Jan;19(1):79-86 [13619024.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):677-81 [8594425.001]
  • [Cites] Herz. 2009 Aug;34(5):410-1 [19711037.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):388-92 [20139363.001]
  • [Cites] Am J Hematol. 2005 Mar;78(3):167-72 [15726600.001]
  • [Cites] J Thromb Thrombolysis. 2010 Feb;29(2):233-40 [19902146.001]
  • [Cites] Clin Appl Thromb Hemost. 1999 Oct;5 Suppl 1:S72-5 [10726040.001]
  • [Cites] Minerva Cardioangiol. 2001 Oct;49(5):327-33 [11533552.001]
  • [Cites] Ann Oncol. 2005 May;16(5):696-701 [15802275.001]
  • [Cites] Acta Derm Venereol. 2007;87(6):510-6 [17989889.001]
  • [Cites] Ann Surg. 1981 Nov;194(5):648-55 [7294936.001]
  • [Cites] Blood. 2001 Sep 15;98 (6):1662-6 [11535495.001]
  • [Cites] Pharmacotherapy. 2004 Jul;24(7 Pt 2):88S-94S [15317404.001]
  • [Cites] Am J Pathol. 2007 Sep;171(3):1066-77 [17640967.001]
  • [Cites] J Am Acad Dermatol. 1999 Aug;41(2 Pt 1):266-8 [10426901.001]
  • [Cites] Swiss Med Wkly. 2009 Aug 8;139(31-32):438-52 [19685350.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21527-33 [9261172.001]
  • [Cites] N Engl J Med. 2008 Jun 5;358(23):2457-67 [18434646.001]
  • [Cites] Burns. 2006 Dec;32(8):1005-8 [16879922.001]
  • [Cites] N Engl J Med. 1991 May 30;324(22):1565-74 [2027360.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):376-81 [20139357.001]
  • [Cites] Best Pract Res Clin Haematol. 2004 Mar;17(1):23-53 [15171956.001]
  • [Cites] Arch Dermatol. 1988 Sep;124(9):1387-91 [3415283.001]
  • [Cites] Hautarzt. 2008 May;59(5):382-93 [18777639.001]
  • [Cites] Ann Dermatol Venereol. 2001 Mar;128(3 Pt 2):352-7 [11319364.001]
  • [Cites] J Invest Dermatol. 2010 May;130(5):1323-8 [20090766.001]
  • [Cites] J Cutan Med Surg. 2002 Jul-Aug;6(4):335-9 [11951132.001]
  • [Cites] Haematologica. 2000 Jan;85(1):72-81 [10629596.001]
  • [Cites] Handb Exp Pharmacol. 2006;(176 Pt 2):1-41 [17001771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16900-5 [17075060.001]
  • (PMID = 20644902.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


21. Case CC, Vassilopoulou-Sellin R: Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia. Endocr Pract; 2003 Jan-Feb;9(1):22-5
Hazardous Substances Data Bank. GLUCAGON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproduction of features of the glucagonoma syndrome with continuous intravenous glucagon infusion as therapy for tumor-induced hypoglycemia.
  • OBJECTIVE: To describe the adverse effects of continuous intravenous infusion of glucagon as therapy for tumor-induced hypoglycemia and to correlate these treatment-related effects with symptoms of endogenous hyper-glucagonemia.
  • METHODS: We reviewed three cases in which patients received continuous glucagon therapy for tumor-induced hypoglycemia and experienced adverse side effects to the treatment.
  • RESULTS: Continuous intravenous glucagon infusion has evolved as a reliable and efficacious modality for the treatment of tumor-induced hypoglycemia.
  • We report the adverse events of venous thromboembolism, necrolytic migratory erythema, and angular cheilitis in conjunction with continuous intravenous glucagon treatment.
  • [MeSH-major] Glucagon / therapeutic use. Glucagonoma / metabolism. Hypoglycemia / drug therapy. Hypoglycemia / etiology. Insulinoma / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Drug Eruptions / pathology. Female. Hemangioma / complications. Humans. Infusions, Intravenous. Lung Neoplasms / complications. Male. Meningeal Neoplasms / complications. Middle Aged. Pleural Neoplasms / complications. Sarcoma / complications






Advertisement